Results
1 -
2 of
2A phase 1 and dose-finding study of LY2523355 (litronesib), an Eg5 inhibitor, in Japanese patients with advanced solid tumors, Cancer Chemotherapy and Pharmacology Two Phase 1 dose-escalation studies exploring multiple regimens of litronesib (LY2523355), an Eg5 inhibitor, in patients with advanced cancer, Cancer Chemotherapy and Pharmacology